Antibodies

Novel agents to control seizures & target epileptogenesis 1:28
Novel agents to control seizures & target epileptogenesis
Claude Steriade • 24 Mar 2022
Real-world studies of CGRP monoclonal antibodies and gepants for migraine 5:33
Real-world studies of CGRP monoclonal antibodies and gepants for migraine
Chia-Chun Chiang • 3 Apr 2022
Investigating α-synuclein aggregation as a therapeutic target in Parkinson’s disease 1:21
Investigating α-synuclein aggregation as a therapeutic target in Parkinson’s disease
Tim Bartels • 17 Mar 2022
Selecting treatment options for NMOSD 1:51
Selecting treatment options for NMOSD
Michael Levy • 3 Apr 2022
The role of neuroprotectors in stroke management 4:41
The role of neuroprotectors in stroke management
Ashfaq Shuaib • 24 Mar 2022
ACTIMIS: Glenzocimab add-on therapy reduces hemorrhage and mortality in ischemic stroke 4:07
ACTIMIS: Glenzocimab add-on therapy reduces hemorrhage and mortality in ischemic stroke
Mikael Mazighi • 9 May 2022
Targeting IL-6 signaling in ischemic stroke 1:28
Targeting IL-6 signaling in ischemic stroke
Marios K. Georgakis • 5 May 2022
Targeting α-synuclein as a therapy for Parkinson’s disease: strategies in the pipeline 1:54
Targeting α-synuclein as a therapy for Parkinson’s disease: strategies in the pipeline
Tiago Outeiro • 18 Mar 2022
Recent hot-button issues in headache research at CONy 2022 2:26
Recent hot-button issues in headache research at CONy 2022
Dimos-Dimitrios Mitsikostas • 22 Mar 2022
New treatments for migraine: who, what, and when? 4:26
New treatments for migraine: who, what, and when?
Jessica Ailani • 11 Apr 2022
How to sequence treatments in migraine 3:00
How to sequence treatments in migraine
Jessica Ailani • 11 Apr 2022
Deep learning can predict treatment response in patients with progressive MS 8:46
Deep learning can predict treatment response in patients with progressive MS
Jean-Pierre Falet • 22 Mar 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab 3:33
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab
Virginia Meca-Lallana • 28 Feb 2022
Advantages of oral anti-CGRP drugs in migraine prevention 14:28
Advantages of oral anti-CGRP drugs in migraine prevention
Sait Ashina • 17 Mar 2022
Impact of ocrelizumab disruption on RRMS 2:52
Impact of ocrelizumab disruption on RRMS
Kelly Cotchett • 25 Feb 2022
The content of VJNeurology is intended for healthcare professionals